ANN ARBOR, Mich., Nov. 29, 2004 (PRIMEZONE) -- Dr. Wilbur Leopold, president of Molecular Imaging Research, Inc., a Michigan based corporation, today announced the company will do business as MIR Preclinical Services. The Company is a contract research organization (CRO) specializing in the preclinical evaluation of novel anti-tumor agents.
"MIR's mission is to non-invasively provide its clients with an integrated correlation of efficacy with pharmacodynamics (mechanism of action) directly applicable to clinical trial. We feel the name change will better represent the services we provide to our target market of pharmaceutical and biotech companies," said Dr. Leopold. "'MIR Preclinical Services' immediately identifies our core business of providing in depth preclinical evaluation of cancer drug candidates."
About MIR Preclincal Services
MIR is a contract research organization specializing in the preclinical evaluation of novel anti-cancer drug candidates. The company boasts management with over 80 years of major pharma cancer drug discovery experience, and is a leader in the integration of traditional anti-cancer efficacy testing with clinically relevant imaging services to provide new insights to drug discovery and development. MIR offers a wide array of tumor models including human tumor xenografts, syngeneic mouse and rat cancers, and oncogene-driven tumors in transgenic mice. The company is unique in its ability to apply state of the art non-invasive imaging modalities including magnetic resonance imaging (MRI), X-ray micro-CT and soon, high resolution preclinical PET to visualize biological processes such as signal transduction, apoptosis and angiogenesis.